-
AcornMed Receives FDA Breakthrough Device Designation for Urothelial Carcinoma Liquid Biopsy
•
Beijing-based tumor precision medicine specialist, AcornMed, has been granted Breakthrough Device Designation (BDD) by the US FDA for its early screening liquid biopsy product, AcornMed utLIFE-UC, designed for detecting urothelial carcinoma. Innovative Liquid Biopsy Technology for Urothelial Carcinoma DetectionThe AcornMed utLIFE-UC product leverages the company’s proprietary database and algorithms to…
-
Baidu Health Partners with HOB Biotech to Innovate Allergy Detection and Treatment
•
Baidu Health has entered into a strategic partnership with HOB Biotech Group, a leading in vitro diagnostic (IVD) specialist in China, to develop a new model that combines allergy detection, desensitization treatment, and Internet+ technologies. The collaboration aims to create a comprehensive approach to allergy management without disclosing financial details.…
-
Tuodao Medical’s Percutaneous Puncture Surgery Robot NP100 Approved in China
•
China-based surgical robot developer Tuodao Medical Technology Co., Ltd has received marketing approval for its percutaneous puncture surgery robot, known as the puncture surgery navigation and positioning system NP100. This approval marks a significant advancement in the field of surgical robotics within the country. Puncture Surgery and Its ChallengesPuncture surgery…
-
CSPC Pharmaceutical Group Receives NMPA Approval for Irinotecan Liposome Injection
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received market approval from the National Medical Products Administration (NMPA) in China for its irinotecan liposome injection. The drug is indicated for the treatment of metastatic pancreatic cancer in patients after gemcitabine treatment and is also used in…
-
Jenscare Scientific’s Tricuspid Valve Replacement System Joins FDA’s TAP Program
•
Ningbo-based structural heart disease device manufacturer Jenscare Scientific Co., Ltd (HKG: 9877) has announced that its in-house developed transcatheter tricuspid valve replacement system product has been included in the Total Product Life Cycle Advisory Program (TAP) of the US FDA. The program’s objective is to ensure that US patients have…
-
Jiangsu Hengrui Pharmaceuticals Entangled in Legal Disputes with BeyondSpring and Reistone
•
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) is currently entangled in legal challenges involving two partner companies. The firm has initiated a lawsuit against US-based biotech BeyondSpring Inc. (NASDAQ: BYSI) over a failed partnership deal, while also facing potential disbandment of its subsidiary, Reistone Biopharma (Hong Kong) Ltd, amid…
-
Astellas Pharma Invests EUR 330 Million in State-of-the-Art Manufacturing Plant in Ireland
•
Japanese pharmaceutical company Astellas Pharma (TYO: 4503) has announced a significant investment of EUR 330 million (USD 352 million) to construct a new manufacturing plant in Ireland. This strategic move aims to enhance the company’s production capacity and ensure a stable global supply of its pharmaceutical products. The state-of-the-art facility…
-
China Launches Fourth National Volume-Based Procurement Tender Focusing on Medical Consumables
•
The national high-value medical consumables joint procurement office has released a notification, marking the commencement of the fourth national-scale volume-based procurement (VBP) tender. This round focuses on artificial lenses and sports medicine medical consumables, with the Tianjin Medical Purchase Center taking on the responsibility of managing the joint procurement office’s…
